Cover Image
市場調查報告書

白細胞介素2受體次單元α (TAC抗原/p55/CD25/IL2RA):開發平台分析

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 361640
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素2受體次單元α (TAC抗原/p55/CD25/IL2RA):開發平台分析 Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 60 Pages
簡介

本報告提供全球各國的白細胞介素2受體次單元α (TAC抗原或p55或CD25或IL2RA)的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

白細胞介素2受體次單元α (TAC抗原/p55/CD25/IL2RA)概要

治療藥的開發

  • 白細胞介素2受體次單元α (TAC抗原/p55/CD25/IL2RA的)開發中產品:概要

在白細胞介素2受體次單元α (TAC抗原/p55/CD25/IL2RA):各企業開發中的治療藥

  • 臨床實驗的各階段
  • 各治療領域
  • 各症狀

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

各企業開發中的治療藥

治療藥的評估

  • 單劑治療藥/並用治療藥的情況
  • 各作用機制
  • 各投藥法
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc.
  • Alkermes Plc
  • APT Therapeutics, Inc.
  • Mabtech Limited
  • Philogen S.p.A.

藥物簡介

  • APT-602
    • 產品概要
    • 作用機制
    • 研究開發 (R&D)的發展情形
  • basiliximab
  • basiliximab的生技改良藥
  • daclizumab
  • Darleukin
  • RDB-1450

開發暫停的產品

值得注意的最新趨勢、新聞稿 (共15件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1081TDB

Summary:

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 2 and 1 respectively. Report covers products from therapy areas Immunology, Oncology and Cardiovascular which include indications Melanoma, Systemic Lupus Erythematosus, Autoimmune Disorders, Blood Cancer, Diffuse Large B-Cell Lymphoma, Kidney Transplant Rejection, Metastatic Melanoma, Ovarian Cancer, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Solid Tumor and Stroke.

The latest report Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
    • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
    • Alkermes Plc
    • Celgene Corp
    • Medicenna Therapeutics Corp
    • Nektar Therapeutics
    • Philogen SpA
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
    • ALKS-4230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APT-602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basiliximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basiliximab biobetter - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • daclizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Darleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Daromun - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEL-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDNA-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NKTR-358 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
      • Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London
      • Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta
      • Jun 09, 2017: EMA reviews multiple sclerosis medicine Zinbryta
      • May 03, 2017: Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program
      • Apr 10, 2017: Biogen's Zinbryta accepted for use in NHS Scotland
      • Mar 27, 2017: Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting
      • Mar 27, 2017: Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders
      • Mar 15, 2017: Nice Recommends Biogen's Zinbryta (Daclizumab) For Relapsing-Remitting Multiple Sclerosis
      • Dec 09, 2016: Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA (Daclizumab Beta) for Multiple Sclerosis
      • Sep 15, 2016: New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA (Daclizumab) and Support Long-Term Safety Profile
      • Sep 08, 2016: Biogen Demonstrates Data on ZINBRYTA at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis
      • Aug 15, 2016: Diplomat to Dispense ZINBRYTA for the Treatment of Multiple Sclerosis
      • Jul 05, 2016: Biogen and AbbVie's Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
      • May 27, 2016: Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosi
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Alkermes Plc, H2 2017
  • Pipeline by Celgene Corp, H2 2017
  • Pipeline by Medicenna Therapeutics Corp, H2 2017
  • Pipeline by Nektar Therapeutics, H2 2017
  • Pipeline by Philogen SpA, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top